Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing cellular
heterogeneity, but it is currently impractical on large sample cohorts and cannot be applied …

We introduce CIBERSORT, a method for characterizing cell composition of complex tissues
from their gene expression profiles. When applied to enumeration of hematopoietic subsets …

The extent of tumor heterogeneity is an emerging theme that researchers are only beginning
to understand. How genetic and epigenetic heterogeneity affects tumor evolution and …

High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate
personalized cancer therapy. However, low quantities of cell-free DNA (cfDNA) in the blood and …

Machine learning (ML) is increasingly used in clinical oncology to diagnose cancers, predict
patient outcomes, and inform treatment planning. Here, we review recent applications of ML …

ctDNA analysis enables detection of MRD and predicts relapse after definitive treatment for
solid cancers, thereby promising to revolutionize personalization of adjuvant and …

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors
(ICIs) can produce remarkably durable responses, most patients develop early disease …

Molecular profiles of tumors and tumor-associated cells hold great promise as biomarkers of
clinical outcomes. However, existing data sets are fragmented and difficult to analyze …